176 related articles for article (PubMed ID: 34772748)
1. Factors that influence clinicians' decisions to decrease active surveillance monitoring frequency or transition to watchful waiting for localised prostate cancer: a qualitative study.
Lowenstein LM; Choi NJ; Hoffman KE; Volk RJ; Loeb S
BMJ Open; 2021 Nov; 11(11):e048347. PubMed ID: 34772748
[TBL] [Abstract][Full Text] [Related]
2. Qualitative study on decision-making by prostate cancer physicians during active surveillance.
Loeb S; Curnyn C; Fagerlin A; Braithwaite RS; Schwartz MD; Lepor H; Carter HB; Sedlander E
BJU Int; 2017 Jul; 120(1):32-39. PubMed ID: 27611479
[TBL] [Abstract][Full Text] [Related]
3. Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions.
Loeb S; Zhou Q; Siebert U; Rochau U; Jahn B; Mühlberger N; Carter HB; Lepor H; Braithwaite RS
Eur Urol; 2017 Dec; 72(6):899-907. PubMed ID: 28844371
[TBL] [Abstract][Full Text] [Related]
4. Perceived barriers to the adoption of active surveillance in low-risk prostate cancer: a qualitative analysis of community and academic urologists.
Ellis SD; Hwang S; Morrow E; Kimminau KS; Goonan K; Petty L; Ellerbeck E; Thrasher JB
BMC Cancer; 2021 May; 21(1):649. PubMed ID: 34058998
[TBL] [Abstract][Full Text] [Related]
5. Radical prostatectomy versus deferred treatment for localised prostate cancer.
Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
[TBL] [Abstract][Full Text] [Related]
6. Barriers and enablers of active surveillance for prostate cancer: a qualitive study of clinicians.
Pattenden TA; Thangasamy IA; Ong WL; Samaranayke D; Morton A; Murphy DG; Evans S; Millar J; Chalasani V; Rashid P; Winter M; Vela I; Pryor D; Mark S; Loeb S; Lawrentschuk N; Pritchard E
BJU Int; 2024 Feb; 133 Suppl 3():48-56. PubMed ID: 37696615
[TBL] [Abstract][Full Text] [Related]
7. Patient Factors That Influence How Physicians Discuss Active Surveillance With Low-Risk Prostate Cancer Patients: A Qualitative Study.
Brooks JV; Ellis SD; Morrow E; Kimminau KS; Thrasher JB
Am J Mens Health; 2018 Sep; 12(5):1719-1727. PubMed ID: 29973123
[TBL] [Abstract][Full Text] [Related]
8. Quantifying the Transition from Active Surveillance to Watchful Waiting Among Men with Very Low-risk Prostate Cancer.
Van Hemelrijck M; Garmo H; Lindhagen L; Bratt O; Stattin P; Adolfsson J
Eur Urol; 2017 Oct; 72(4):534-541. PubMed ID: 27816297
[TBL] [Abstract][Full Text] [Related]
9. Utilization of Active Surveillance and Watchful Waiting for localized prostate cancer in the daily practice.
Herden J; Weissbach L
World J Urol; 2018 Mar; 36(3):383-391. PubMed ID: 29330583
[TBL] [Abstract][Full Text] [Related]
10. Radical prostatectomy versus watchful waiting for prostate cancer.
Hegarty J; Beirne PV; Walsh E; Comber H; Fitzgerald T; Wallace Kazer M
Cochrane Database Syst Rev; 2010 Nov; (11):CD006590. PubMed ID: 21069689
[TBL] [Abstract][Full Text] [Related]
11. The psychological impact of being on a monitoring pathway for localised prostate cancer: A UK-wide mixed methods study.
Matheson L; Wilding S; Wagland R; Nayoan J; Rivas C; Downing A; Wright P; Brett J; Kearney T; Cross W; Glaser A; Gavin A; Watson E
Psychooncology; 2019 Jul; 28(7):1567-1575. PubMed ID: 31132801
[TBL] [Abstract][Full Text] [Related]
12. Long-term Psychological and Quality-of-life Effects of Active Surveillance and Watchful Waiting After Diagnosis of Low-risk Localised Prostate Cancer.
Egger SJ; Calopedos RJ; O'Connell DL; Chambers SK; Woo HH; Smith DP
Eur Urol; 2018 Jun; 73(6):859-867. PubMed ID: 28851582
[TBL] [Abstract][Full Text] [Related]
13. Patient perspective on watchful waiting/active surveillance for localized prostate cancer.
Xu J; Neale AV; Dailey RK; Eggly S; Schwartz KL
J Am Board Fam Med; 2012; 25(6):763-70. PubMed ID: 23136314
[TBL] [Abstract][Full Text] [Related]
14. Primary Care Physician and Urologist Perspectives on Optimizing Active Surveillance for Low-Risk Prostate Cancer.
Radhakrishnan A; Subramanian L; Rankin AJ; Fetters MD; Wittmann DA; Ginsburg KB; Hawley ST; Skolarus TA
Ann Fam Med; 2024; 22(1):5-11. PubMed ID: 38253492
[TBL] [Abstract][Full Text] [Related]
15. Patient reported factors influencing the decision-making process of men with localised prostate cancer when considering Active Surveillance-A systematic review and thematic synthesis.
Cunningham M; Murphy M; Sweeney P; Richards HL
Psychooncology; 2022 Mar; 31(3):388-404. PubMed ID: 34605104
[TBL] [Abstract][Full Text] [Related]
16. The experience of adults who choose watchful waiting or active surveillance as an approach to medical treatment: a qualitative systematic review.
Rittenmeyer L; Huffman D; Alagna M; Moore E
JBI Database System Rev Implement Rep; 2016 Feb; 14(2):174-255. PubMed ID: 27536798
[TBL] [Abstract][Full Text] [Related]
17. The New Surveillance, Epidemiology, and End Results Prostate with Watchful Waiting Database: Opportunities and Limitations.
Jeong CW; Washington SL; Herlemann A; Gomez SL; Carroll PR; Cooperberg MR
Eur Urol; 2020 Sep; 78(3):335-344. PubMed ID: 31980309
[TBL] [Abstract][Full Text] [Related]
18. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
19. Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial.
Wade J; Donovan J; Lane A; Davis M; Walsh E; Neal D; Turner E; Martin R; Metcalfe C; Peters T; Hamdy F; Kockelbergh R; Catto J; Paul A; Holding P; Rosario D; Kynaston H; Rowe E; Hughes O; Bollina P; Gillatt D; Doherty A; Gnanapragasam VJ; Paez E
BMJ Open; 2020 Sep; 10(9):e036024. PubMed ID: 32907896
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.
Sathianathen NJ; Konety BR; Alarid-Escudero F; Lawrentschuk N; Bolton DM; Kuntz KM
Eur Urol; 2019 Jun; 75(6):910-917. PubMed ID: 30425010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
